Role of Gene Profiling Assays in Early-Stage HR+ Breast Cancer
The role of gene profiling assays in identifying candidates for chemotherapy in early HR-positive breast cancer.
CancerNetw_HRBreast_CC_Seg03_Assays
Video Player is loading.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Diagnosis and Management of mCSPC
The Oncotype DX Breast Recurrence Score for HR+ Breast Cancer
Genomic Testing vs Genetic Testing for HR+ Breast Cancer
Genomic Assays and Adjuvant Therapy for HR+ Breast Cancer
Informed Decision-Making in HR+ Breast Cancer
Neoadjuvant Therapy for HR+ Breast Cancer
NCCN Guidance on Gene Profiling in Early-Stage HR+ Breast Cancer
Gene Profile-Directed Therapy for Early-Stage HR+ Breast Cancer
The Oncotype DX Breast Recurrence Score: Clinical Trial Data
Perioperative Decision-Making in HR+ Breast Cancer
Related Content
Treatment Options in Metastatic Castration-Sensitive Prostate Cancer
March 13th 2022Article
In this program Atish D. Choudhury, MD, PhD, discusses recent updates on long-term safety and efficacy data in patients with metastatic castration-sensitive prostate cancer and the importance of patient communication and quality of life while on treatment.
